Document Detail

Omega-3 Fatty Acids and Mortality Outcome in Patients With and Without Type 2 Diabetes After Myocardial Infarction: A Retrospective, Matched-Cohort Study.
MedLine Citation:
PMID:  23246017     Owner:  NLM     Status:  Publisher    
BACKGROUND: There are conflicting data regarding the benefits of omega-3 (n-3) fatty acids, most recently in patients with type 2 diabetes. OBJECTIVE: Our goal was to evaluate the impact of licensed, highly purified n-3 fatty acids on all-cause mortality after myocardial infarction (MI). METHODS: This was a retrospective, matched-cohort study using data from the General Practice Research Database. Patients initiating treatment with 1 g of n-3 fatty acids in the 90 days after first MI were identified and each matched to 4 nonexposed patients. Progression to death was compared using time-dependent Cox models to account for potential differences in exposure to other cardiovascular risk-modifying treatments. RESULTS: A total of 2466 eligible subjects exposed to n-3 fatty acids were matched. The majority of patients had concurrent treatment with lipid-lowering therapies, antihypertensives, and antiplatelets after first MI, with subjects exposed to n-3 fatty acids having a greater likelihood of concurrent exposure. For those initiating n-3 fatty acids within 90 days of first MI, the adjusted hazard ratio (aHR) was 0.782 (95% CI, 0.641-0.995; P = 0.0159); for those initiating treatment within 14 days, the aHR was 0.680 (95% CI, 0.481-0.961; P = 0.0288). In patients with type 2 diabetes at baseline, the aHRs were 0.714 (95% CI, 0.454-1.124) and 0.597 (95% CI, 0.295-1.211) when initiation was within 90 and 14 days, respectively. Use of n-3 fatty acids resulted in a consistent survival benefit under a range of scenarios quantitatively consistent with the overall effect. CONCLUSION: After MI, early treatment with licensed n-3 fatty acids was associated with improvement in all-cause mortality in patients with and without type 2 diabetes, against a background of contemporary cardiovascular risk-modifying treatments.
Chris D Poole; Julian P Halcox; Sara Jenkins-Jones; Emma S M Carr; Mathias G Schifflers; Kausik K Ray; Craig J Currie
Related Documents :
23183517 - N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.
8142417 - Modulation of gtp-dependent fusion by linoleic and arachidonic acid in derivatives of r...
1156477 - Effect of early oral feeding on plasma free fatty acid concentrations in patients in a ...
16666997 - Manipulating membrane fatty acid compositions of whole plants with tween-fatty acid est...
3411437 - Determination of gamma-aminobutyric acid and associated amino acids in mouse brain by l...
7901387 - Effects of two substituted hydrazine monoamine oxidase (mao) inhibitors on neurotransmi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-12
Journal Detail:
Title:  Clinical therapeutics     Volume:  -     ISSN:  1879-114X     ISO Abbreviation:  Clin Ther     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
Department of Primary Care and Public Health, School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff MediCentre, Cardiff, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantitative therapy response assessment by volumetric iodine-uptake measurement: Initial experience...
Next Document:  Cor a 1-reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch ...